Trials / Terminated
TerminatedNCT01153958
Colposeptine for the Treatment of Bacterial Vaginosis
The Use of Colposeptine in Bacterial Vaginosis. A Randomized, Controlled Study
- Status
- Terminated
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 133 (actual)
- Sponsor
- Merck KGaA, Darmstadt, Germany · Industry
- Sex
- Female
- Age
- 18 Years – 45 Years
- Healthy volunteers
- Not accepted
Summary
This is a prospective, randomized, controlled and multi-center trial to assess the use of colposeptine in female subjects with bacterial vaginosis. A total of 480 subjects were planned to be enrolled in various centers in China.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Colposeptine | Colposeptine will be administered transvaginally at a dose of 1 capsule every day for 12 consecutive days |
| DRUG | Metronidazole | Metronidazole will be administered orally at a dose of 400 mg twice a day for 7 days |
Timeline
- Start date
- 2010-07-01
- Primary completion
- 2010-11-01
- Completion
- 2010-11-01
- First posted
- 2010-06-30
- Last updated
- 2014-02-13
- Results posted
- 2012-08-21
Locations
5 sites across 1 country: China
Source: ClinicalTrials.gov record NCT01153958. Inclusion in this directory is not an endorsement.